 |
 |

Structural and Symptomatic Efficacy of Glucosamine and Chondroitin: Relevant Financial Interest?
 |
 |
| Since this article does not have an abstract, we have provided the first 100 words of the full text and any section headings. |
|
 |
 |
In their article, Richy et al1 declare "no relevant financial interest in this article." I note, however, that one of the key trials2 cited in their systematic review (reference 24) was by some of the same authors. The Lancet study was sponsored by Rotta Research Laboratorium, Milan, Italy, who markets their product as a medicinal agent in various European Union countries and may be seeking to market their product as a medicinal agent in the United Kingdom. Under these circumstances, it would seem appropriate for the authors to declare their connection with Rotta, at least in terms of previous funding.
Paresh Jobanputra, DM, FRCP(Edin)
Birmingham, England
1. Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis. Arch Intern Med. 2003;163:1514-1522.
FREE FULL TEXT
2. Reginster JY, Deroisy R, Rovati RC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357:251-256.
FULL TEXT
|
ISI
| PUBMED
Arch Intern Med. 2004;164:338-339.
RELATED ARTICLES
Structural and Symptomatic Efficacy of Glucosamine and Chondroitin: Relevant Financial Interest?Reply
Jean-Yves Reginster
Arch Intern Med. 2004;164(3):339.
EXTRACT
| FULL TEXT
Structural and Symptomatic Efficacy of Glucosamine and Chondroitin in Knee Osteoarthritis: A Comprehensive Meta-analysis
Florent Richy, Olivier Bruyere, Olivier Ethgen, Michel Cucherat, Yves Henrotin, and Jean-Yves Reginster
Arch Intern Med. 2003;163(13):1514-1522.
ABSTRACT
| FULL TEXT
|